RxPrep
On November 30, 2020, the Company issued a press release announcing that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company’s New Drug Application (NDA) submission for belumosudil (KD025), the Company's Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of patients with chronic graft-versus-host disease (cGVHD). ................
................
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.